Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Swan Ganz catheter

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Swan Ganz catheter. Displaying page 1 of 1.
    EudraCT Number: 2007-003059-36 Sponsor Protocol Number: Bay 58-2667/12480 Start Date*: 2007-12-10
    Sponsor Name:Bayer Healthcare AG
    Full Title: Placebo controlled, randomized, double-blind, multi-center, multinational Phase IIb study to investigate the efficacy and tolerability of BAY 58-2667 given intravenously in patients with acute deco...
    Medical condition: Patients with acute decompensated chronic congested heart failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064653 Acute decompensated heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended) EE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) SI (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014377-40 Sponsor Protocol Number: Bay 58-2667/14560 Start Date*: 2010-01-08
    Sponsor Name:Bayer Healthcare AG
    Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenousl...
    Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064653 Acute decompensated heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) AT (Prematurely Ended) SK (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014378-16 Sponsor Protocol Number: Bay 58-2667/14663 Start Date*: 2010-01-14
    Sponsor Name:Bayer Healthcare AG
    Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of Low Dose BAY 58-2667 (25 μg/h, 10 μg/h) Given Intravenously ...
    Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064653 Acute decompensated heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001225-16 Sponsor Protocol Number: 3001077 Start Date*: 2004-10-28
    Sponsor Name:Orion Pharma
    Full Title: Survival of patients with acute heart failure in need of intravenous inotropic support; a multicentre parallel- group, randomised, double- blind, double- dummy study of levosimendan versus dobutami...
    Medical condition: Acutely decompensated heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017082-39 Sponsor Protocol Number: Bay 58-2667 / 14836 Start Date*: 2010-02-01
    Sponsor Name:Bayer Healthcare AG
    Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 μg/h, 100 μg/h, 150 μg/h) Given Intravenousl...
    Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064653 Acute decompensated heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) IE (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-002835-17 Sponsor Protocol Number: 250774 Start Date*: 2016-01-18
    Sponsor Name:Justus Liebig Universität Gießen
    Full Title: Investigation of the influence of PAH-specific medication on right ventricular function in patients with pulmonary arterial hypertension (PAH) under basal conditions
    Medical condition: Pulmonary arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037403 Pulmonary hypertension NOS LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077729 Pulmonary arterial hypertension WHO functional class III LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077740 Pulmonary arterial hypertension WHO functional class II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003055-60 Sponsor Protocol Number: RIO-40400 Start Date*: 2014-10-10
    Sponsor Name:Medical University of Vienna
    Full Title: Evaluation of the pharmacodynamic effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction in a randomized, double blind, placebo controlled, ...
    Medical condition: Pulmonary hypertension and heart failure with preserved ejection fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005992-81 Sponsor Protocol Number: CL-N-CSM-III/01/08 Start Date*: 2011-03-21
    Sponsor Name:Dr. F. Köhler Chemie GmbH
    Full Title: A Prospective Randomized Double Blind Multicenter Phase III Study Comparing two Methods of Cardioplegia in Coronary Artery Bypass Surgery Custodiol-N versus Custodiol
    Medical condition: The study population will be selected from both genders with coronary artery disease (CAD) who are to undergo cardiopulmonary bypass for coronary artery bypass surgery. The ratio of incidence for b...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000855-11 Sponsor Protocol Number: HJE-STEROHCA-001 Start Date*: 2020-09-11
    Sponsor Name:Department of Cardiology, Copenhagen University Hospital Rigshospitalet
    Full Title: STEROID TREATMENT AS ANTI-INFLAMMATORY AND NEUROPROTECTIVE AGENT FOLLOWING OUT-OF-HOSPITAL CARDIAC ARREST. A RANDOMIZED TRIAL.
    Medical condition: We investigate the efficacy of commercially available glucocorticoid "methylprednisolone" (Solu-Medrol) for reducing the systemic inflammatory response and neurological injury in patients resuscita...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10003109 Arrest cardiac LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-023839-42 Sponsor Protocol Number: H8O-CY-O027 Start Date*: 2011-04-29
    Sponsor Name:General University Hospital in Prague
    Full Title: EXEnatide in patients undergoing Coronary artery bypass grafting for improved glUcose conTrol and hemodynamIc ValuEs
    Medical condition: Patients with elective coronary artery bypass grafting with LV systolic dysfunction (EF LV ≤ 50%)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10011077 Coronary artery bypass PT
    14.1 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015878-35 Sponsor Protocol Number: BAY63-2521/14308 Start Date*: 2010-03-22
    Sponsor Name:Bayer Healthcare AG
    Full Title: Randomized, double blind, placebo controlled, parallel group, multi-center study to evaluate the hemodynamic effects of Riociguat (BAY 63-2521) as well as safety and kinetics in patients with pulmo...
    Medical condition: Pacientes sintomáticos con una hipertensión pulmonar asociada a una disfunción del ventrículo izquierdo (PH-sLVD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Trial now transitioned) NL (Completed) BE (Completed) AT (Completed) FR (Completed) GB (Completed) IT (Trial now transitioned) DK (Completed) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006843-29 Sponsor Protocol Number: CKI-303 Start Date*: 2007-06-13
    Sponsor Name:NovaCardia Inc
    Full Title: A multicentre, randomized, double-blind, placebo controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms, diuresis, renal function, and clinical outcomes ...
    Medical condition: Patients being admitted to hospital with heart failure and volume overload requiring IV therapy after experiencing worsening of renal function.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed) PL (Completed) GR (Completed) BE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:54:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA